Department of Orthopaedics and Trauma Surgery, University Clinic Aachen, RWTH Aachen University Clinic, Aachen, Germany.
Department of Medicine, Surgery and Dentistry, University of Salerno, via S. Allende, Baronissi (SA), Italy.
Expert Rev Clin Pharmacol. 2021 May;14(5):635-641. doi: 10.1080/17512433.2021.1903316. Epub 2021 Mar 22.
: Chronic low back pain (LBP) is common, and some patients require opiates therapy. This Bayesian network meta-analysis (NMA) analyzed available randomized clinical trials (RCTs) on the use of opioids for LBP.: All RCTs comparing two or more opioids for chronic LBP and reporting results under the Numeric Rating Scale were included. The following drugs were analyzed: fentanyl, morphine, tapentadol, oxycodone, buprenorphine, oxymorphone, tramadol. The NMA was performed through the STATA routine for Bayesian hierarchical random-effects model analysis, with standardized mean difference (SMD) effect measure. Data regarding the rate of adverse events and different drug formulations were also reported.: Data from 2933 patients were obtained, with a mean age of 53.30 ± 6.95 years. The mean duration of symptoms prior to beginning the trial was 95.16 ± 47.29 months. The mean follow-up was 3.29 ± 1.72 months. Among the analyzed compounds, oxymorphone, tapentadol and fentanyl showed the highest efficacy in terms of pain reduction.: According to published level I evidence, oxymorphone, tapentadol and fentanyl were the most effective drugs in the treatment of chronic LBP. However, different formulation and pharmacokinetic characteristics need to be taken into consideration when choosing the ideal compound for a given patient.
慢性下腰痛(LBP)很常见,有些患者需要阿片类药物治疗。这项贝叶斯网络荟萃分析(NMA)分析了关于阿片类药物治疗 LBP 的现有随机临床试验(RCT)。
所有比较两种或多种阿片类药物治疗慢性 LBP 并报告数值评分量表结果的 RCT 均被纳入。分析的药物有:芬太尼、吗啡、曲马多、羟考酮、丁丙诺啡、奥施康定。通过 STATA 常规进行贝叶斯分层随机效应模型分析,采用标准化均数差(SMD)效应量进行 NMA。还报告了不良反应发生率和不同药物制剂的数据。
从 2933 名患者中获得数据,平均年龄为 53.30±6.95 岁。试验前症状持续时间的平均值为 95.16±47.29 个月。平均随访时间为 3.29±1.72 个月。在分析的化合物中,羟考酮、曲马多和芬太尼在减轻疼痛方面的疗效最高。
根据已发表的 I 级证据,羟考酮、曲马多和芬太尼是治疗慢性 LBP 最有效的药物。然而,在为特定患者选择理想的化合物时,需要考虑不同的制剂和药代动力学特征。